CELZ Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.020

Open

1.990

VWAP

1.96

Vol

11.31K

Mkt Cap

7.17M

Low

1.930

Amount

22.20K

EV/EBITDA(TTM)

--

Total Shares

3.70M

EV

84.31K

EV/OCF(TTM)

--

P/S(TTM)

806.56

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.

Show More

Events Timeline

(ET)

2026-01-13

09:30:00

Creative Medical Technology Releases Interim Data for CELZ-201 Clinical Trial

2026-01-06 (ET)

2026-01-06

09:30:00

Creative Medical Technology Receives Approval to Advance BioDefense Burn Pit Initiative

2025-12-17 (ET)

2025-12-17

09:20:00

Creative Medical Technology Completes Patient Enrollment in CELZ-201 Clinical Trial

2025-12-02 (ET)

2025-12-02

09:30:00

Creative Medical Technology Receives WHO Approval for Olastrocel as INN for CELZ-201

2025-11-21 (ET)

2025-11-21

16:32:54

Creative Medical to Offer 2.79 Million Shares of Common Stock for Shareholders

2025-10-30 (ET)

2025-10-30

09:19:59

Creative Medical Introduces Veterans Initiative for Biodefense Inc.

2025-10-29 (ET)

2025-10-29

09:08:34

Creative Medical Reveals Warrant Exercise Agreements Expected to Generate $4.2M in Proceeds

2025-10-27 (ET)

2025-10-27

08:26:31

Creative Medical Sends Letter to Shareholders

2025-08-13 (ET)

2025-08-13

09:09:30

Creative Medical secures FDA Fast Track designation for CELZ-201-DDT

News

Newsfilter

02-10Newsfilter

Creative Medical Achieves Second International Nonproprietary Name Milestone

NASDAQ.COM

01-16NASDAQ.COM

Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes

NASDAQ.COM

01-13NASDAQ.COM

Creative Medical Technologies Reports Positive CELZ-201 Interim Data, Significant Pain Relief Achieved

Globenewswire

01-13Globenewswire

Creative Medical Reports Positive Interim Data for CELZ-201 in Chronic Back Pain Trial

Globenewswire

01-06Globenewswire

Creative Medical Receives Approval to Advance Veterans' Burn Pit Initiative

NASDAQ.COM

2025-12-18NASDAQ.COM

Creative Medical Completes Enrollment for ADAPT Trial on Chronic Lower Back Pain

Valuation Metrics

The current forward P/E ratio for Creative Medical Technology Holdings Inc (CELZ.O) is -1.26, compared to its 5-year average forward P/E of -1.48. For a more detailed relative valuation and DCF analysis to assess Creative Medical Technology Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.48

Current PE

-1.26

Overvalued PE

0.52

Undervalued PE

-3.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

1187.11

Current PS

8605.62

Overvalued PS

4096.04

Undervalued PS

-1721.81

Financials

AI Analysis

Annual

Quarterly

Whales Holding CELZ

Trading Trends

People Also Watch

Frequently Asked Questions

What is Creative Medical Technology Holdings Inc (CELZ) stock price today?

The current price of CELZ is 1.94 USD — it has decreased -1.52

What is Creative Medical Technology Holdings Inc (CELZ)'s business?

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.

What is the price predicton of CELZ Stock?

Wall Street analysts forecast CELZ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELZ is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Creative Medical Technology Holdings Inc (CELZ)'s revenue for the last quarter?

Creative Medical Technology Holdings Inc revenue for the last quarter amounts to 3.00K USD, decreased 0.00

What is Creative Medical Technology Holdings Inc (CELZ)'s earnings per share (EPS) for the last quarter?

Creative Medical Technology Holdings Inc. EPS for the last quarter amounts to -0.70 USD, decreased -35.78

How many employees does Creative Medical Technology Holdings Inc (CELZ). have?

Creative Medical Technology Holdings Inc (CELZ) has 4 emplpoyees as of March 31 2026.

What is Creative Medical Technology Holdings Inc (CELZ) market cap?

Today CELZ has the market capitalization of 7.17M USD.